Paper

The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

Published Feb 1, 2000 · W. March, K. Ochsner

American Journal of Ophthalmology

Citations

Influential Citations

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

RCTLarge Human Trial

Study Snapshot

Brinzolamide 1.0% effectively reduces intraocular pressure in primary open-angle glaucoma and ocular hypertension patients for 18 months, with minimal ocular discomfort.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension

References

Citations